Principal Financial Group Inc. Has $14.84 Million Stock Position in Immunocore Holdings plc (NASDAQ:IMCR)

Principal Financial Group Inc. reduced its holdings in Immunocore Holdings plc (NASDAQ:IMCR) by 8.0% in the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 502,857 shares of the company’s stock after selling 43,461 shares during the quarter. Principal Financial Group Inc. owned approximately 1.01% of Immunocore worth $14,835,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IMCR. China Universal Asset Management Co. Ltd. increased its position in shares of Immunocore by 69.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 7,433 shares of the company’s stock worth $231,000 after buying an additional 3,053 shares during the period. GSA Capital Partners LLP acquired a new stake in shares of Immunocore during the third quarter worth $406,000. Alpha DNA Investment Management LLC acquired a new stake in shares of Immunocore during the third quarter worth $411,000. XTX Topco Ltd increased its position in shares of Immunocore by 72.9% during the third quarter. XTX Topco Ltd now owns 15,459 shares of the company’s stock worth $481,000 after buying an additional 6,516 shares during the period. Finally, Verition Fund Management LLC acquired a new stake in shares of Immunocore during the third quarter worth $739,000. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on IMCR shares. HC Wainwright reiterated a “buy” rating and set a $100.00 price objective on shares of Immunocore in a research report on Monday, January 27th. Morgan Stanley reiterated an “equal weight” rating and set a $35.00 price objective (down from $74.00) on shares of Immunocore in a research report on Friday, December 13th. Needham & Company LLC reiterated a “buy” rating and set a $71.00 price objective on shares of Immunocore in a research report on Friday, January 10th. Finally, Mizuho cut shares of Immunocore from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $72.00 to $38.00 in a report on Monday, November 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $65.64.

Immunocore Stock Up 5.3 %

Immunocore stock opened at $30.77 on Thursday. Immunocore Holdings plc has a 1-year low of $27.69 and a 1-year high of $72.56. The firm has a market capitalization of $1.54 billion, a price-to-earnings ratio of -32.39 and a beta of 0.77. The firm’s fifty day moving average price is $30.03 and its two-hundred day moving average price is $31.96. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.